Wednesday, October 30, 2024

4:55 PM - 5:40 PM

---

Overview

Sponsored by: TELIX

---

Details

The global radiopharmaceuticals market is poised for significant growth, with a forecasted value of over $21 billion by 2032 and growing 10 per cent annually. Australian Biotech is at the forefront of this new wave of radiopharmaceutical innovations, set to transform patient outcomes and unlock the sector's potential. This session highlights several key Australian listed and unlisted radiopharmaceutical biotechnology companies together with a panel session discussing some of the advantages and challenges in succeeding in one of the fastest growing sectors in precision oncology and medical science.

---

Speaker